Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18702638 | 0.94 | TSHR (0.48) | IDO1HTTALDH1A1TSHRBLM | |
| SCHEMBL57131 | 0.86 | IDO1 (0.50) | IDO1 | |
| SCHEMBL29357487 | 0.77 | IDO1 (0.57) | IDO1HTTTSHRADRA2AADRA1A | |
| SCHEMBL145977 | 0.77 | IDO1 (0.57) | IDO1HTTTSHRADRA2AADRA1A | |
| SCHEMBL13082165 | 0.76 | IDO1 (0.55) | IDO1HTTALDH1A1TSHRBLM | |
| SCHEMBL4756410 | 0.75 | IDO1 (0.50) | IDO1HTTALDH1A1TSHRBLM | |
| SCHEMBL3812210 | 0.75 | IDO1 (0.50) | IDO1HTTALDH1A1TSHRBLM | |
| SCHEMBL5732694 | 0.75 | IDO1 (0.50) | IDO1HTTALDH1A1TSHRBLM | |
| SCHEMBL177082 | 0.75 | IDO1 (0.50) | IDO1HTTALDH1A1TSHRBLM | |
| SCHEMBL1705439 | 0.74 | IDO1 (0.53) | IDO1HTTALDH1A1TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854632-A | Synthesis method and application of large-steric-hindrance heteroatom compound | 深圳职业技术学院 | 2023-10-10 | — | — | CN | claimed |
| CN-111747827-A | Biphenyl triphenol compound and preparation method and application thereof | 南方科技大学 | 2020-10-09 | — | — | CN | claimed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | claimed |
| US-20150239889-A1 | PYRAZOLOPYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-27 | — | — | US | claimed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | claimed |
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | claimed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | claimed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | claimed |
| US-5185460-A | Reacting hydrogen cyanide with desired mercaptan; recovering salt; intermediates for funcicides, herbicides, dyes, perfumes | NIPPON SODA CO., LTD. (JP) | 1993-02-09 | — | — | US | claimed |
| EP-0378707-B1 | AMINOACETONITRILE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 1993-01-20 | — | — | EP | claimed |
| EP-0378707-A1 | AMINOACETONITRILE DERIVATIVES. | NIPPON SODA CO (JP) | 1990-07-25 | — | — | EP | claimed |
| WO-1990000543-A1 | AMINOACETONITRILE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 1990-01-25 | — | — | WO | claimed |
| EP-0211004-A1 | USE OF ACYL UREA COMPOUNDS FOR CONTROLLING ENDOPARASITES AND ECTOPARASITES OF WARM-BLOODED ANIMALS | RHONE-POULENC NEDERLAND B.V. (NL) | 1987-02-25 | — | — | EP | claimed |
| WO-1986003941-A1 | USE OF ACYL UREA COMPOUNDS FOR CONTROLLING ENDOPARASITES AND ECTOPARASITES OF WARM-BLOODED ANIMALS | UNION CARBIDE CORPORATION (US) | 1986-07-17 | — | — | WO | claimed |
| US-4369189-A | INSECTICIDES, MITICIDES NEMATOCIDES | UNION CARBIDE CORPORATION (US) | 1983-01-18 | — | — | US | claimed |
| EP-0001267-B1 | MASS COLORATION OF LINEAR POLYESTERS | CIBA-GEIGY AG (CH) | 1981-09-16 | — | — | EP | claimed |
| US-4231918-A | THIOINDIGO OR DIOXAZINE PIGMENT AND DYE | CIBA-GEIGY CORPORATION (US) | 1980-11-04 | — | — | US | claimed |
| US-3948877-A | POLYACRYLONITRILE, ACID MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239889-A1 | PYRAZOLOPYRIMIDINE COMPOUND | HIF1AN, EGLN2, EGLN3 | IDO1 1056/4885HTT 1001/4885ALDH1A1 379/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | IDO1 2430/4885HTT 1138/4885ALDH1A1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.